Genomic Health Rating Reiterated by Canaccord Genuity (GHDX)
Genomic Health (NASDAQ:GHDX)‘s stock had its “hold” rating restated by equities research analysts at Canaccord Genuity in a research note issued to investors on Monday. They currently have a $27.00 target price on the stock, down from their previous target price of $30.00. Canaccord Genuity’s target price suggests a potential upside of 3.25% from the company’s current price.
Genomic Health (NASDAQ:GHDX) traded down 0.54% on Monday, hitting $26.01. The stock had a trading volume of 103,873 shares. Genomic Health has a 52 week low of $23.90 and a 52 week high of $37.24. The stock’s 50-day moving average is $26.71 and its 200-day moving average is $27.23. The company’s market cap is $815.0 million.
Genomic Health (NASDAQ:GHDX) last released its earnings data on Tuesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.11. The company had revenue of $70.50 million for the quarter, compared to the consensus estimate of $69.04 million. During the same quarter in the previous year, the company posted ($0.10) earnings per share. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. Analysts expect that Genomic Health will post $-0.84 EPS for the current fiscal year.
Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.